Telehealth firm Hims & Hers will launch low-testosterone treatments for men on Wednesday, starting with enclomiphene plans priced $99-$199/month. The company plans to expand into women's hormonal therapies for perimenopause and menopause. Hims says it's targeting 50 million Americans with overlooked hormonal health issues. Stock sentiment is 'bullish'.